The scientific strengths of the Virginia CSCC serve as a strong foundation for a robust plan for a prospective sickle cell scholar's recruitment, career development, scientific development, and placement in a career of sickle cell investigation. The pool for recruitment will come from training programs in internal medicine and pediatrics, and fellowship programs in child and adult hematology/oncology. Scholars can attain funding and training for a minimum of two to and a maximum of three years, depending on their level of training and their progress toward productivity in external funding. The career development of the scholar will be the primary responsibility of both the Virginia SCSS PI and one of 5 scientific mentors, a mentoring committee that will meet with the scholar monthly. All mentors have a 10-20 year NIH funding record, and 10 or more trainees each now pursuing research. The clinical development of the scholar will consist of strong and prolonged, guided, inpatient and outpatient exposure to sickle cell disease in either or both pediatric and adult settings, depending on the trainee's clinical background in pediatrics or adult medicine. If the scholar chooses to obtain additional training to qualify him/her to sit for specialty boards in hematology/oncology, that training will be obtained in cooperation with the training program of the scholar's choosing, and could be done prior to or after the scholar's training in sickle cell disease. The clinical development of the scholar will consist of strong and prolonged, guidied, inpatient and outpatient exposure to sickle cell disease in either or both pediatric and adult settings, depending on the trainee's clinical background in pediatrics or adult medicine. The scholar may choose to obtain additional training to qualify him/her to sit for specialty boards in hematology/oncology, in cooperation with the training program of the scholar's choosing. The scientific didiactic and experiential curriculum of the scholar will feature broad training in sickle cell disease, plus intense training in the research laboratory or clinical research environment of the chosen mentor. Mentors are working in one of three available research tracks, which correspond to the foci of the three research teams of the Virginia CSCC research program. Experience at the NIH's clinical program in vascular biology will be available to the trainee(s). Placement of the scholar into an initial academic career will be the goal of training.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HL090516-03
Application #
8261358
Study Section
Special Emphasis Panel (ZHL1)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
3
Fiscal Year
2011
Total Cost
$148,264
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Smith, Wally R; McClish, Donna K; Dahman, Bassam A et al. (2015) Daily home opioid use in adults with sickle cell disease: The PiSCES project. J Opioid Manag 11:243-53
Ameringer, Suzanne; Elswick Jr, R K; Smith, Wally (2014) Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health-related quality of life. J Pediatr Oncol Nurs 31:6-17
Redmond, Latasha C; Pang, Christopher J; Dumur, Catherine et al. (2014) Laser capture microdissection of embryonic cells and preparation of RNA for microarray assays. Methods Mol Biol 1092:43-60
Alsalman, Abdulkhaliq J; Smith, Wally R (2013) Expanding the framework of assessing adherence and medication-taking behavior. J Pain Palliat Care Pharmacother 27:114-24
Dampier, Carlton D; Smith, Wally R; Wager, Carrie G et al. (2013) IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials 10:319-31
Dampier, Carlton D; Wager, Carrie G; Harrison, Ryan et al. (2012) Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes. Am J Hematol 87:E71-4
Pang, Christopher J; Lemsaddek, Wafaa; Alhashem, Yousef N et al. (2012) Kruppel-like factor 1 (KLF1), KLF2, and Myc control a regulatory network essential for embryonic erythropoiesis. Mol Cell Biol 32:2628-44
Peters-Lawrence, Marlene H; Bell, Margaret C; Hsu, Lewis L et al. (2012) Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials 33:291-7
Dampier, Carlton D; Smith, Wally R; Kim, Hae-Young et al. (2011) Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. Am J Hematol 86:E70-3
Sogutlu, Aslihan; Levenson, James L; McClish, Donna K et al. (2011) Somatic symptom burden in adults with sickle cell disease predicts pain, depression, anxiety, health care utilization, and quality of life: the PiSCES project. Psychosomatics 52:272-9

Showing the most recent 10 out of 23 publications